Axoft Announces Commercialization of Fleuron, Covered by an Exclusive License Agreement with Stanford University
Many iBCIs struggle to maintain a stable, high-density interface with soft biological tissues over the long term due to their rigidity and limited biocompatibility. Fleuron addresses this challenge by mimicking the mechanical properties of brain tissue. Resembling a rubber-like version of Teflon, Fleuron offers both longitudinal stability as thin-film material and is compatible with high-density neural interface microfabrication, while minimizing disruption to brain tissues. The material enables new applications for biomedical micro-electromechanical systems (bioMEMS), organ-on-a-chip and implantable devices, and can be used in micro- and nano-fabrication to make high-density microelectrode arrays capable of capturing stable single-neuron electrical activity for more than a year and a half, based on preclinical models.
Dr. Jia Liu, co-founder and scientific advisor of Axoft, initiated the development of Fleuron while at Stanford during his postdoctoral training in Professor Zhenan Bao's research group. Dr. Liu went on to join Harvard University as Assistant Professor of Bioengineering, where he worked with Axoft co-founder and CEO Dr. Paul Le Floch to improve the scalability of Fleuron for a wide range of bioelectronics applications. The related intellectual property developed at Stanford was recently licensed exclusively to Axoft for applications in iBCIs for the treatment of neurological disorders, bioMEMS, bioelectronics and other devices.
'Fleuron is up to 10,000x softer than the polyimide or Parylene C used by most iBCI companies and up to 1,000,000x softer than silicon. It's specifically designed to improve the stability of the tissue-electronics interface, reduce scar tissue and prevent implant drift within the brain over time,' said Dr. Le Floch. 'Fleuron can be used for a wide range of applications where hardware meets biology, including biohybrid devices, organ-on-a-chip, microfluidics and neural interfaces. It includes a platform of materials that are extremely biocompatible yet highly performant and capable of integrating with scalable manufacturing techniques. The broader research and industry landscape stands to benefit from Fleuron, as it has the potential to become a new standard in biomedical engineering.'
Several industrial and academic organizations are already using Fleuron for their own research and development. Axoft uses custom Fleuron formulations in its iBCI devices, which have resulted in unmatched biocompatibility, long-term signal stability and a high bandwidth interface that maximizes the information exchanged between the brain and electronics.
The first Fleuron products are available for purchase today for use as soft, negative photoresists for microfabrication. Axoft plans to launch more material formulations by the end of 2025 for additional biomedical engineering applications.
About Axoft
Founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft is building implantable Brain-Computer Interfaces (iBCIs) leveraging bio-inspired materials to enable a seamless interface between the brain and electronics, and allow for measurement and stimulation at high-resolution in any brain region. Axoft is on a mission to unlock new treatments for patients suffering from neurological disorders by producing iBCIs that answer critical unmet needs. For more information, visit www.axoft.us or follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Circus SE Gets Awarded International Red Dot Award 'Best of Best' for Outstanding Industrial Design
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global technology leader in AI software and robotics for the food service industry, has been awarded the prestigious international Red Dot Award for outstanding industrial design in the 'Best of the Best' category – the highest recognition in the annual Red Dot Awards. As one of the most respected global design awards, the Red Dot Award honors groundbreaking innovation across industries. With this rare distinction, Circus joins the ranks of Google, Ferrari, and Apple – whose MacBook Pro and AirPods Pro have previously earned the same honor. The CA-1 was honored in the 'Ready for Market' category which is eligible only to products that are market-ready. This category recognizes innovations that have completed the design journey and are poised for commercial deployment at scale. With serial production underway and commercial deployment beginning this fall, Circus SE's CA-1 Series 4 perfectly meets the award's criteria. Following the upcoming ceremony in October, the iconic CA-1 design will be featured in the Red Dot Winner Exhibition at the Red Dot Design Museum in Singapore, where it will be showcased to an international audience of innovators, designers, and technologists. 'This award is a powerful validation of the vision and discipline that went into the CA-1,' said Nikolas Bullwinkel, CEO and Founder of Circus SE. 'We always wanted to build a system that people trust, understand, and enjoy interacting with – something truly designed for everyday life.' The design of the CA-1 was developed in collaboration with renowned German industrial designer Mario Selic, known for his work in advanced robotics and consumer innovation with companies such as KUKA, Siemens, and Bosch and was subsequently refined and engineered for serial production by Circus' in-house teams. 'From the early sketches, the ambition was to create something radically functional yet architecturally clear – a robotic system that integrates seamlessly into human spaces,' said Selic. 'We were inspired by Edward Hopper's Nighthawks, the Airstream trailer, and Bauhaus principles – clean geometry, minimalism, and design that disappears into its surroundings while elevating them.' 'CA-1 began with a strong conceptual foundation, and throughout the design maturation, we remained committed to preserving the original design intent. We wanted to develop an autonomous product that feels effortless – for the operator, the environment, and the customer,' added Gustavo Kemmerich, Head of Mechanical Engineering and Industrial Design at Circus SE, who was instrumental over the years in bringing the CA-1 to serial manufacturing. This recognition cements Circus SE's role as a pioneer at the intersection of robotics, design, and everyday human experience – redefining how machines live, work, and serve among us. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply – on a mission to fuel humanity. About Red Dot The Red Dot Design Award is one of the world's most prestigious honors for outstanding design. Each year, an international jury recognizes exceptional achievements across Product Design, Brands & Communication Design, and Design Concept. With submissions from over 60 countries, Red Dot is regarded as a global benchmark for innovation, design excellence, and business differentiation. Its highest honor – 'Best of the Best' – is internationally recognized and has been awarded to groundbreaking designs and products from companies such as Apple, Google, and Ferrari. With its museum in Singapore and global visibility, the Red Dot Design Award continues to shape the role of design in both technological and societal transformation.
Business Wire
2 hours ago
- Business Wire
Indian Aircraft Manufacturing Company Raphe mPhibr Revolutionizes Unmanned Aerial Vehicle Innovation with Dassault Systèmes' 3DEXPERIENCE Platform
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, today announced that Raphe mPhibr, India's most innovative aircraft manufacturing company specializing in unmanned aerial vehicles, has adopted its 3DEXPERIENCE platform to transform how aircraft systems are conceived, validated and built, substantially reducing the design cycle. Unmanned aircraft systems are emerging in light of growing applications in defense, homeland security, agriculture, logistics and infrastructure monitoring, and are expected to reach an estimated 6.5 million units in 2030. To contribute to India's goal of becoming self-reliant in aerospace and defense, Raphe mPhibr needed a new approach to integrate technology and advanced scientific principles into its design process for the engineering of next-generation UAVs with superior strength-to-weight performance and increased payload capacity. From metals to composites and electronics, Raphe mPhibr designs and builds everything under one roof. Dassault Systèmes' 3DEXPERIENCE platform significantly reduced its product development cycle while integrating physics and design for manufacturing within the design phase. One of the most compelling use cases for the 3DEXPERIENCE platform at Raphe mPhibr was during the development of its engine. Traditionally a multi-year effort, the engine development process was shortened to just three months. The platform empowered the team to redesign parts optimized for 3D manufacturing. 1 Raphe mPhibr successfully created complex composite parts through an integrated design and simulation workflow. It reduced the weight of its 4kW 2-stroke engine, which outperforms systems seven times its weight, by 700 grams (1.54 pounds), and made a strategic shift toward 3D-centric design thinking that led to more intuitive and efficient part development. The platform also enabled the team to push the boundaries of engineering by designing high-performance aerodynamic surfaces. 'Designing and manufacturing a drone is nothing less than designing and manufacturing a whole aircraft. The kind of drones we are manufacturing have 20,000 to 30,000 parts,' said Vikash Mishra, Chairman, Raphe mPhibr. 'The 3DEXPERIENCE platform allows us to think in 3D – not in straight lines, circles or squares. Biological systems that have evolved in nature – such as plants, anatomical structures and geological formations – are not made up of geometrical shapes. So, using this platform, we can design more organically and without limitations. It's the best software to create our vision.' 'Raphe mPhibr's adoption of our 3DEXPERIENCE platform shows how innovators are building tomorrow's advanced air mobility solutions with virtual twin experiences. Its focus on in-house design sets a new benchmark for engineering excellence,' said David Ziegler, Vice President, Aerospace and Defense Industry, Dassault Systèmes. 'The 3DEXPERIENCE platform combines all aspects of design, simulation and collaboration in a single environment for innovation and operational efficiency.' Raphe mPhibr recently announced it closed $100 million in funding in a round led by General Catalyst - the largest private funding round for an Indian aircraft manufacturer to date. Raphe mPhibr has a team of over 500 people and more than 100 unique intellectual property assets. Its products have logged over one million kilometers (621,371 miles) with the security forces of India. Raphe mPhibr's future roadmap includes growing its workforce, expanding its research, development and manufacturing facility, and using virtual twin experiences for lifecycle management. Dassault Systèmes' 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions:
Business Wire
4 hours ago
- Business Wire
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. ICP-B794 is developed from InnoCare's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients. Share ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others. Currently, there are no B7-H3 targeted therapies approved for marketing globally. B7-H3 is a type I transmembrane protein that is highly expressed in a variety of solid tumors. Due to its specific expression in tumor cells, it is considered a highly promising anti-tumor target. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "ICP-B794 is developed from the Company's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology." With ongoing efforts to address the growing needs in solid tumors, InnoCare is committed to building a competitive drug portfolio aimed at treating a broad range of solid tumor indications. The Company is expanding the scope of its pipeline through a combination of targeted therapies, immune-oncology approaches, and cutting-edge ADC technology. The R&D team is focused on discovering and developing novel platforms that target various solid tumors, utilizing innovative technologies to identify and advance potential drug candidates that offer significant clinical benefits. InnoCare's proprietary ADC technology platform, alongside promising precision medicine candidates like TRK inhibitor zurletrectinib (ICP-723), positions the Company to establish a strong presence in the field of solid tumor treatment. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
